REVIEW
New targets for the therapy of Pulmonary Arterial Hypertension (PAH) Nebulized anti-miRs against miR-138 and miR-25 completely regress monocrotaline-induced PAH
 
More details
Hide details
1
Academic Department of Pneumonology, Hospital for Diseases of the Chest, “Sotiria”, Medical School, University of Athens, Messogion Avenue 152, Athens, Greece
2
Division of Immunology, Biomedical Sciences Research Center “Alexander Fleming”, Vari, Athens, Greece
CORRESPONDING AUTHOR
Argyris Tzouvelekis   

Biomedical Sciences Research Center “Alexander Fleming”, Division of Immunology, Vari 16672, Athens, Greece
Publication date: 2021-06-16
 
Pneumon 2016;29(3):236–237
 
 
REFERENCES (7)
1.
Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121:2045-66.
 
2.
Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USAbased registry for pulmonary arterial hypertension: 1982-2006. ERJ 2007;30:1103-10.
 
3.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012;142:448-56.
 
4.
Hong Z, Chen KH, Dasgupta A, et al. miR-138 and miR-25 Downregulate MCU, Causing Pulmonary Arterial Hypertension’s Cancer Phenotype. American Journal of Respiratory and Critical Care Medicine 2016.
 
5.
Santulli G, Xie W. Mitochondrial calcium overload is a key determinant in heart failure. 2015;112:11389-94.
 
6.
Pan L, Huang BJ, Ma XE, et al. MiR-25 protects cardiomyocytes against oxidative damage by targeting the mitochondrial calcium uniporter. International Journal of Molecular Sciences 2015;16:5420-33.
 
7.
Yan H, Zhang D, Hao S, Li K, Hang CH. Role of Mitochondrial Calcium Uniporter in Early Brain Injury After Experimental Subarachnoid Hemorrhage. Molecular Neurobiology 2015;52:1637-47.
 
eISSN:1791-4914
ISSN:1105-848X